Board summary
Key figures
62,862
Registered population
61.0% aged 18–64
18.9%
Aged 65+
ICB 14.9% · England 17.9%
42.3%
In IMD quintile 1
ICB 40.7% · England 21.0%
~25,244
Core20 residents (est.)
Resident basis; registered basis ~26,849 · see page 3
12,050
Hypertension register
+12.67% in 3 yrs · England +5.60%
783
SMI register
21.9% of Wigan (LAD)'s
1,758
COPD register
Reviews +5.51% in 3 yrs
Forecast to 2030
15,604
Hypertension patients, 2030
+3,554 on today
61.5%
QRISK ≥20% on statins, 2030
-0.41pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension treatment to target exceeds national benchmark.
Across 12,050 registered hypertension patients, 77.1% are treated to target against 75.6% in Wigan (LAD), 71.4% in the ICB and 70.3% in England.
Asthma review coverage trails England and ICB.
Annual asthma review coverage is 61.9% (England 65.7%, ICB 66.2%), leaving an estimated scale of 1,653 of 4,339 register patients without a review.
Population, age and ethnicity
Older adults make up 18.9% of the list alongside 891 care home beds
Across 62,862 registered patients, 18.9% are aged 65+ (11,875 patients), above Wigan (LAD) (18.8%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Children aged 0–17 make up 20.2% (12,670; LAD 20.0%, ICB 21.8%, England 19.6%) and adults aged 18–64 form 61.0% (38,317; LAD 61.6%, ICB 63.3%, England 62.7%). Projected population growth to 2030 is 1.0% (LAD 1.1%, ICB 1.6%, England 2.3%), using unverified methods. Census resident data records Gypsy or Irish Traveller and Roma groups each at 0.1% (LAD 0.1%, ICB 0.1%, England 0.1% and 0.2%). The catchment includes 24 care homes with 891 beds.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Wigan (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wigan LA) | 2,706 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wigan LA) | 1,243 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wigan LA) | 12.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 42.3% and spans 75.0 percentage points across practices
Across Wigan Central PCN, 42.3% of registered patients live in Core20 areas, above England (21.0%) and Wigan (LAD) (29.4%), with an average IMD decile of 4.0. Practice shares span 75.0 pp, from 11.4% at Dr Seabrook to 86.4% at Marsh Green Medical Practice. Pemberton Surgery holds the highest volume at 5,707 estimated Core20 patients. Practice estimates sum to 26,849, compared with 25,244 estimated Core20 residents. Targeting requires balancing intensive neighbourhood outreach at high-concentration practices with clinical capacity at high-volume sites.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
783
SMI register
1.22% recorded prevalence
482
Learning disability register
0.75% recorded prevalence
24
Care homes, 891 beds
In the PCN catchment
10.1%
Provide unpaid care
Wigan (LAD), Census 2021
Severe mental illness prevalence is 1.2% (783 patients), above Wigan (LAD) (1.0%), NHS Greater Manchester Integrated Care Board (1.1%) and England (1.0%). Learning disability prevalence is 0.8% (482 patients; LAD 0.7%, ICB 0.6%, England 0.6%). These crude recorded register rates do not establish undiagnosed disease, under-detection or unmet need.
Severe mental illness: physical health checks
Across 783 severe mental illness register patients, annual blood pressure checks fell 1.1 pp to 77.8% over 2023 to 2025 (England +4.4 pp to 83.4%) and BMI recording fell 0.7 pp to 77.6% (England +5.1 pp to 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,050
Hypertension register
+12.67%
Register growth, 3 yrs
Wigan (LAD) +10.59% · England +5.60%
+5.65pp
BP control, under 80
≤140/90 · +1.66pp aged 80+
+3,554
More patients by 2030
Forecast 15,604 (23.93%)
Hypertension case-finding and control
Recorded hypertension prevalence is 18.9% (12,050 patients), above Wigan (LAD) (18.0%), England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%). Over 2023 to 2025, prevalence increased by +12.7% (England +5.6%, Wigan (LAD) +10.6%). Process and control indicators show: 91.5% had a recent blood pressure check (England 90.0%), and 77.1% were treated to target (England 70.3%). Among patients aged under 80, control reached 75.2% (England 67.8%), while in patients aged 80 and over it reached 85.7% (England 81.2%, Wigan (LAD) 86.4%). Crude rates do not account for age structure. Blood pressure control rates exceed national comparators across both age cohorts, though control in patients aged 80 and over remains 0.7 percentage points below Wigan (LAD).
Lipids and statins
Lipid therapy in patients with QRISK ≥ 20% is 62.4%, below Wigan (LAD) (64.0%), England (63.6%) and NHS Greater Manchester Integrated Care Board (67.0%), after a 3-year change of -0.7% over 2023 to 2025 (England +6.2%). Primary prevention lipid-lowering therapy trails all comparators following a three-year decline.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 126,962 | £1.90 | £1.94 | £1.86 | £241,228 |
| Cardiovascular (all), 2025 | 178,751 | £3.88 | £3.15 | £3.33 | £693,554 |
For lipid-modifying drugs in 2026, the PCN prescribed 126,962 items at £1.90 per item, below Wigan (£2.09) and the ICB (£1.94), but above England (£1.86), representing £5,078 more than at England's unit cost across 126,962 items. Unit spend is close to national and regional benchmarks, so clinical review of lipid therapy reach should take precedence over formulary unit-cost adjustments.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.28%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.30%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.8% (1,758 patients; England 1.9%, Wigan (LAD) 2.6%) following +11.2% growth over 2023 to 2025 (England +2.6%); 75.3% had an annual review (England 76.4%). Asthma prevalence is 7.2% (4,339 patients; England 6.6%) and annual review coverage is 61.9% (England 65.7%, Wigan (LAD) 64.4%), leaving an estimated scale of 1,653 unreviewed patients. In ages 5-19, asthma prescribing is 2,521 per 1,000 (England 1,488), while second-hand smoke recording in ages 6-19 is 67.2% (England 78.8%).
Cancer register and children's immunisation
The cancer register includes 2,626 patients (4.1% prevalence; England 3.8%). In Q1 2025/26 childhood immunisations, Wigan Central PCN exceeds national uptake across routine vaccines, including 6-in-1 at 24 months (96.3% vs England 92.2%) and MMR dose 1 at age 5 (96.5% vs England 91.7%). However, MMR dose 2 (90.1%) and 4-in-1 booster (90.1%) remain 4.9 pp below the 95.0% target.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2 across NHS Greater Manchester ICB, compared to 55.3% in England and the 75.0% national ambition. Known-stage cancers represented 70.8% of 16,492 registered cases. Locally, Wigan Central PCN cervical screening coverage is 68.9% (Wigan 73.0%, England 66.8%), with Sullivan Way Surgery at 61.7% and Pemberton Surgery at 66.6%. ICB staging data reflects system presentation rather than PCN performance, but lower screening uptake could delay detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, the 62-day referral to treatment standard was 8.2 pp below the 85.0% operational standard, while 31-day combined treatment was 7.0 pp below its 96.0% standard. Conversely, 28-day faster diagnosis exceeded the 75.0% standard by 7.8 pp. Across NHS Greater Manchester Integrated Care Board, 28-day faster diagnosis was 4.5 pp above the 75.0% standard, while 62-day waits trailed the 85.0% standard. These figures describe acute trust and system performance rather than PCN delivery.
| Pathways within standard (%) | Wrightington, Wigan and Leigh | Mersey and West Lancashire | Lancashire | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.80 | 72.39 | 82.90 | 79.53 | 79.32 |
| 31-day treatment (96%) | 89.04 | 95.46 | 89.43 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 76.78 | 77.96 | 75.04 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wrightington, Wigan and Leigh | Mersey and West Lancashire | Lancashire | England |
|---|---|---|---|---|
| MRI | 0.49 | 14.04 | 2.41 | 21.40 |
| CT | 7.78 | 13.08 | 14.97 | 9.92 |
| Echocardiography | 24.37 | 34.88 | 13.85 | 28.48 |
| Colonoscopy | 6.10 | 18.04 | 0.00 | 30.83 |
| Gastroscopy | 12.54 | 18.17 | 0.00 | 29.02 |
| All 15 DM01 tests | 14.36 | 21.17 | 26.65 | 23.14 |
| Community services activity | Wigan residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 48,150 | 573,310 |
| Referrals | 13,750 | 94,470 |
| Patients with a contact | 18,695 | 183,535 |
Community services (residents of Wigan), Jun 2026 (provisional). In community health services, contacts with adults aged 65 and over represented 58.5% of all borough residents' contacts (28,190 of 48,150 contacts in Jun 2026 (provisional) data). These community services figures describe borough-level resident activity rather than PCN performance.
Practice variation and patient experience
Phone access spans 42.4 percentage points and vaccination achievement varies by 30.1 percentage points
For 2025/26, QOF clinical-domain achievement is 100.0% at Bradshaw Medical Centre and 97.7% at Newtown Medical Practice, compared to England at 97.1%. QOF vaccination and immunisation-domain achievement spans 30.1 pp across captured practices, from 50.1% at Bradshaw Medical Centre to 80.2% at Pemberton Surgery, against an England figure of 55.2%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Pemberton Surgery | 91 | 56.0 | 80.3% | 70.9% | 97.3% |
| Mesnes View | 119 | 16.9 | 95.1% | 81.4% | 95.8% |
| Dr Seabrook | 113 | 11.4 | 88.2% | 57.4% | 94.7% |
| Newtown Medical | 104 | 52.5 | 84.1% | 71.3% | 92.5% |
| Dicconson | 94 | 42.5 | 72.5% | 63.7% | 89.6% |
| Sullivan Way | 90 | 41.5 | 65.2% | 57.5% | 84.2% |
| Marsh Green | 104 | 86.4 | 76.9% | 73.4% | 83.6% |
| Longshoot Medical | 123 | 42.4 | 56.8% | 64.0% | 79.3% |
| Bradshaw | 110 | 28.6 | 52.7% | 76.0% | 75.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 measures trail England, led by falling severe mental illness checks
Across 25 compared measures, 12 trail England over 2023 to 2025. On the 783-patient severe mental illness register, blood pressure checks fell 1.1 pp to 77.8% (England +4.4 pp to 83.4%), BMI recording fell 0.7 pp to 77.6% (England +5.1 pp to 82.1%), and psychosis alcohol recording fell 3.0 pp to 75.6% (England +5.4 pp to 81.8%). Conversely, diabetes HbA1c control improved +9.7% (England +4.4%), under-80 blood pressure control rose +8.1% (England +3.2%), and heart failure reviews increased +13.2% (England +8.7%), which is consistent with routine chronic disease progress alongside lagging vulnerable cohort checks.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Alcohol record (psychosis)
QRISK statin treatment
BMI record (SMI)
BP check (SMI)
Diabetes HbA1c control
BP control, under 80
Heart failure reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wigan (LAD) | Asset | PCN | Wigan (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 24 (891 beds) | n/a | Schools (catchment) | 81 | n/a |
| Children's centres | 6 | 20 | Places of worship | 61 | 164 |
| Libraries | 3 | 10 | Primary schools (LA maintained) | 18 | 68 |
| Primary academies | 8 | 21 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and smoke recording
Asthma annual review coverage is 61.9% (Wigan (LAD) 64.4%, ICB 66.2%, England 65.7%) across 4,339 patients, an estimated scale of 1,653 unreviewed patients. For discussion, the PCN could run single-template asthma recall offering after-school slots, reviewing inhaler prescribing and recording second-hand smoke exposure. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Combined severe mental illness health checks
On the 783-patient SMI register, annual BP checks are 77.8% (Wigan (LAD) 84.1%, England 83.4%), falling 1.1 pp over 2023 to 2025 (England +4.4 pp), and BMI recording is 77.6% (England 82.1%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Pharmacist-led lipid therapy recall review
Lipid-lowering therapy in patients with QRISK ≥ 20% is 62.4% (Wigan (LAD) 64.0%, ICB 67.0%, England 63.6%), falling 0.7% (0.4 pp) over 2023 to 2025 (England +6.2%, +3.8 pp). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Provenance and audit trail
Provenance and audit trail
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home visiting alignment (p2) | Count of care home beds in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Two-track Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness health checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older patient blood pressure audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool immunisation call and recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and smoke recording (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Combined severe mental illness health checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Option 3 · Pharmacist-led lipid therapy recall review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) · Items prescribed per 1,000: Lipid-regulating drugs (18+, persons, 2026) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
